Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | PRESIDENT AND CFO | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,060 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 55,000 · Balance 79,060 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2031-09-08 | Direct | 57,405 |
Reported balance
After 2026-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-02 · Exercise / conversion · Disposed 55,000 · Balance 57,405 F1: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 20:59 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · derivative · entry 2 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,405 Underlying: Common Stock · 55,000 shares Expires 2031-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 20:59 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionCommon Stock | 55,000 | $2.32 | $127,600.00 |
DisclosureSEC source: 0002009130-26-000006 · wk-form4_1791233964.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 24,056 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 9 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,818 Underlying: Common Stock · 24,056 shares Expires 2033-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | SaleCommon Stock | 886 | $26.87 | $23,806.82 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 6 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | SaleCommon Stock | 23,170 | $25.78 | $597,290.16 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 5 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,946 F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionCommon Stock | 24,056 | $2.35 | $56,531.60 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 4 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 54,375 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 8 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,625 Underlying: Common Stock · 54,375 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 56,455 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · derivative · entry 7 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,874 Underlying: Common Stock · 56,455 shares Expires 2033-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | SaleCommon Stock | 110,830 | $26.58 | $2,946,149.56 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 3 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2 · price: This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionCommon Stock | 54,375 | $2.35 | $127,781.25 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 2 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 05:33 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Exercise / conversionCommon Stock | 56,455 | $2.35 | $132,669.25 |
DisclosureSEC source: 0002009130-26-000004 · wk-form4_1790904813.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 19:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Tax withholdingCommon Stock | 2,806 | $19.69 | $55,250.14 |
DisclosureSEC source: 0002009130-26-000002 · wk-form4_1772583322.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 F1 · shares: Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 17:18 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0002009130-26-000001 · wk-form4_1771021115.xml · derivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-02-10 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 135,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 10 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 9 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F7 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $14.88 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 8 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 7 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F6 · derivative.exercise_date: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 202,329 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 6 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 202,329 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 202,329 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 5 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,329 Underlying: Common Stock · 202,329 shares Expires 2033-12-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 33,833 | Not disclosed Strike: $6.23 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 4 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,833 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,833 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 3 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,833 Underlying: Common Stock · 33,833 shares Expires 2033-04-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 44,962 | Not disclosed Strike: $6.23 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 2 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,962 shares Expires 2032-09-21 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 17:20 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 44,962 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000062 · wk-form4_1752009629.xml · derivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,962 Underlying: Common Stock · 44,962 shares Expires 2032-09-21 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 16:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001999480-25-000015 · wk-form4_1738963337.xml · derivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 16:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 4,550 | $16.56 | $75,348.00 |
DisclosureSEC source: 0001415889-24-009533 · form4-04012024_040402.xml · nonDerivative · entry 2 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,866 Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 16:15 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 1,600 | $15.80 | $25,280.00 |
DisclosureSEC source: 0001415889-24-009533 · form4-04012024_040402.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,316 Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 18:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001415889-24-006823 · form4-03052024_060303.xml · derivative · entry 2 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-28 F3 · derivative.exercise_date: 25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 18:00 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantCommon Stock | 19,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006823 · form4-03052024_060303.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,716 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person's continuous service through each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of common stock. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 16:40 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | PurchaseCommon Stock | 1,563 | $16.00 | $25,008.00 |
DisclosureSEC source: 0001415889-24-002940 · form4-02072024_090252.xml · nonDerivative · entry 1 Smith Nicholas Conrad · CIK 0002009130 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,563 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.